Next-generation, high-speed DNA-decoding technology detects minimal residual disease in nearly double the number of leukemia patients than current gold standard method
Next-generation, high-speed DNA-decoding technology detects minimal residual disease in nearly double the number of leukemia patients than current gold standard method